Key result
Discontinuation of sulpiride and maprotiline was associated with the development of neuroleptic malignant syndrome and acute myoglobinuric renal failure in a 46-year-old man.
Case Report (n=1)
No
This is the first reported case of neuroleptic malignant syndrome and acute myoglobinuric renal failure following the discontinuation of sulpiride and maprotiline.
Answers are grounded in this paper and cite their sources.
May indicate NMS risk after sulpiride/maprotilline withdrawal; first case leaves causality and incidence open.
A 46-year-old man developed neuroleptic malignant syndrome with acute myoglobinuric renal failure after the discontinuation of sulpiride and maprotiline treatment. He showed the characteristic features of hyperpyrexia, altered consciousness, muscle rigidity, and autonomic dysfunction. Laboratory data showed lysis of skeletal muscle cells and renal impairment. Muscle biopsy revealed necrosis and regenerative changes in muscle fibers. Renal biopsy showed focal tubulitis and interstitial infiltration of small inflammatory cells. The combination of sulpiride and maprotiline has not previously been reported to be the cause of neuroleptic malignant syndrome and acute myoglobinuric renal failure.
No takes yet. Share an insight, caveat, or question.
Kiyatake et al. (1991) conducted a case report in Neuroleptic malignant syndrome with acute renal failure (n=1). Discontinuation of sulpiride and maprotiline was evaluated on Development of neuroleptic malignant syndrome and acute myoglobinuric renal failure. Discontinuation of sulpiride and maprotiline was associated with the development of neuroleptic malignant syndrome and acute myoglobinuric renal failure in a 46-year-old man.
Synapse has enriched 10 related papers. Consider them for comparative context: